天坛生物(600161.SH)：上半年净利润6.33亿元 同比下降12.88%

Core Viewpoint - Tian Tan Biological Products (600161.SH) reported a total operating revenue of 3,110.39 million yuan for the first half of 2025, reflecting a year-on-year growth of 9.47%, while the net profit attributable to shareholders decreased by 12.88% [1] Group 1 - The increase in operating revenue is attributed to a growth in sales volume [1] - The decline in net profit is influenced by a decrease in product sales prices and changes in credit policies leading to reduced interest income [1] - The company operated 85 plasma collection companies, achieving a plasma collection of 1,361 tons, which represents a year-on-year increase of 0.7% [1]